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Background: The information provided in patient-centered care and shared decision-making influences patients’
concerns and adherence to treatment. In the decision-making process, patients experience decisional conflict. The
Decisional Conflict Scale (DCS) is a 16-item, self-administered questionnaire consisting of 5 subscales developed to
assess patients’ decisional conflict. This study aimed to develop the Japanese version of the DCS and to clarify the
influence of the information provided by pharmacists’ on decisional conflict among patients with cancer.
Methods: We developed the Japanese version of the DCS by using the forward-backward translation method. One
hundred patients who were recommended a new chemotherapy regimen were recruited. The psychometric
properties of the Japanese DCS, including internal consistency, convergent validity, discriminant validity, and
construct validity, were examined. We assessed the decisional conflict of patients before and after the pharmacists’
provision of information.
Results: Ninety-four patients, predominately female, with an average age of 58.1 years were sampled. The scores
on the 5 subscales of the DCS showed high internal consistency (Cronbach’s alpha = 0.84–0.96). Multi-trait scaling
analysis and cluster analysis showed strong validity. The mean total DCS score decreased significantly from 40.2 to
31.7 after patients received information from the pharmacists (p < 0.001, paired t-test). Scores on all 5 subscales,
namely, uncertainty, informed, values clarity, support, and effective decision, also significantly improved (p < 0.001
for all categories, paired t-test).
Conclusions: The psychometric properties of the Japanese version of the DCS are considered appropriate for it to
be administered to patients with cancer. Pharmacists’ provision of information was able to decrease decisional
conflict among patients with cancer who were recommended a new chemotherapy regimen.
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In recent years, patient-centered care and shared
decision-making have been recognized as essential fac-
tors in oncology practice [1,2]. Because patient estimates
of the risk/benefit of treatments vary, and because some
therapeutic options have undesirable outcomes, patients
with cancer may experience uncertainty and face diffi-
cult decisions [3-8]. Uncertainty and difficult options are
likely to cause patients to experience decisional conflict
[9]. O’Connor et al. defined a state of uncertainty
concerning which course of action to take as decisional
conflict and developed the Decisional Conflict Scale
(DCS) to evaluate the decisional conflict that patients
experience regarding the health care decision-making
process [9].
The DCS is divided into five subscales of uncertainty,
informed, values clarity, support, and effective decision-
making, and is composed of 16 items that use a 5-point
Likert-type response (i.e., strongly agree, agree, neither
agree nor disagree, disagree, and strongly disagree). De-
cisional conflict was calculated from calculating the total
scores obtained on these 16 items. The uncertainty
subscale estimates the degree of uncertainty a patient
faces in decision-making. Informed, values clarity, and
support subscales are considered modifiable factors that
contribute to uncertainty and represent feelings of being
uninformed, the clarity of personal values, and feelings
of being unsupported, respectively. The effective deci-
sion subscale measures the combination of informed
choice, patient response value, and satisfaction. The
total score and the score on each subscale are calcu-
lated according to the DCS user’s manual and both can
range from 0 to 100, with 100 indicating extremely
high decisional conflict. An effect size of 0.3 to 0.4 is
assumed to be a meaningful difference [10]. A total
score <25 is associated with decision implementation,
while a total score ≥37.5 is associated with decision
delay or indecision. Previous studies have indicated
that decisions supporting intervention can ameliorate
decisional conflict [10].
Understanding the information that a patient requires,
particularly regarding the knowledge of treatment op-
tions, is essential in the decision-making process
[11-13]. During diagnosis, nearly all patients require in-
formation on treatment, side effects, extent of disease,
prognosis, and self-care [14]. Following treatment, pa-
tients would need information regarding treatment and
recovery. Thus, these information needs and preferences
can alter during the course of treatment [15]. In Japan,
little research has been conducted on decisional conflict
and patients’ perception of treatment in the decision-
making process on patients with cancer. Medical pater-
nalism, which is termed the “omakase” (entrusting)
model in Japan, has existed in the Japanese physician-patient communication for many years [16]. This model,
however, has been changing in the past decade. For ex-
ample, Horikawa and colleagues reported that the per-
centage of information disclosure to patients with cancer
had risen to 71% in the late 1990s from 27% in the early
1990s [17]. In response to these changes, there is a
growing awareness among medical professionals that in-
formation provided to patients and patients’ attitudes to-
ward participation in decision-making are essential to
clinical practice in Japan [18,19]. In addition, patient
satisfaction with information provided about medication
affects their concern and adherence [20-22]. A responsi-
bility of a pharmacist is to educate patients by providing
treatment information [23]. A provision of information
is a process of decision, and a decisional conflict is an
outcome of decision. Therefore, we hypothesized that
pharmacists’ provision of information regarding treat-
ment would influence the decisional conflict in patients
during decision-making. In addition, the development of
instrument measuring decision outcome, the Japanese
version of the DCS, is essential for assessment of phar-
macists’ provision of information.
The aim of the present study was two-fold. First, we
aimed to develop the Japanese version of the DCS and
to examine the internal consistency, as well as the con-
struct, criterion, and factorial validity in patients with
cancer who were recommended a new chemotherapy
regimen. Second, we aimed to analyze the influence of
pharmacists’ provision of information on decisional con-
flict in patients with cancer.Methods
Development of the Japanese version of the DCS
The DCS has three versions, namely, statement format,
question format, and low literacy. The statement format
(based on responses on statements with responses ran-
ging from strongly agree to strongly disagree.), which is
the one used in this study, has 16 items (e.g., “I am clear
about which benefits matter most to me”) and five re-
sponse categories. The statement format of the DCS was
translated into Japanese through the forward-backward
translation method [24]. Two native Japanese speakers
conducted the forward translation. One of the transla-
tors was informed of the aim and concept of the ques-
tionnaire but the other was not. After the translations of
both of the translators were synthesized, two translators
back-translated the synthesized questionnaire into English.
The two latter translators were native English language pro-
fessionals without a medical background, and were not in-
formed of the aim or concept of the questionnaire. After a
pilot test to evaluate problems about semantic, idiomatic,
and cognitive issues by using a hypothetical scenario of
treatment choice with 40 health care providers, including
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finalized the Japanese version of the DCS.
Measurements
Decisional conflict
Each participant completed the Japanese version of the
DCS before and after pharmacists’ provision of informa-
tion. The repeated measurements result in random er-
rors, which caused regression to the mean (RTM) [25].
Therefore, to reduce the effects of RTM, baseline deci-
sional conflict was measured twice.
Baseline quality of life
This study included patients with various types of cancer
and settings. Thus, participants may have various dys-
function and symptoms. Baseline quality of life (QOL)
score, including assessment of function and symptoms,
is known as a prognostic factor for survival in patients
with cancer [26]. To assess the correlation between
baseline QOL, a self-administered European Organisa-
tion for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire (QLQ)-C30 version 3.0 (30
items) was completed by the patients before the pharma-
cist provided information. The EORTC QLQ-C30 is
composed of five functional scales (physical, role, emo-
tional, cognitive, and social functioning), a global health
status/QOL scale, three symptom scales (fatigue, pain,
and nausea/vomiting), and six single items (dyspnea, in-
somnia, appetite loss, constipation, diarrhea, and finan-
cial difficulties). The validity and reliability of the
Japanese version of EORTC QLQ-C30 has been verified
in patients with cancer [27]. All scores were linearly
transformed into scales of 0 to 100, according to the
scoring manual. A higher functional scale score repre-
sented a more favorable status, while a higher symptom
score indicated a poorer status.
Demographics and clinical information
We obtained demographic information, including age,
gender, marital status, level of education, and employ-
ment status, from the patients through the question-
naire. The level of education was classified into three
levels, namely, low (elementary: grades 1–6 and junior
high school: grades 7–9), middle (high school: grades
10–12), and high (university or graduate school: grade
13 or above). Clinical information, such as cancer type,
prior chemotherapy, and chemotherapy type, was
obtained from the patients’ medical records.
Participants
This study was conducted on patients with cancer at
Tokyo Medical University Hospital from June 2011 to
April 2012. The criteria for eligibility were as follows: 20
to 75 years of age, diagnosed with any type of cancer,scheduled for receiving information from a pharmacist,
and recommended for a new chemotherapy regimen. Pa-
tients who were not Japanese or had a serious psychi-
atric disease were excluded. Sample size was calculated
to detect a meaningful difference of decisional conflict
before and after the pharmacists’ provision of informa-
tion. We estimated that 88 patients would be needed for
an effect size of 0.3, a power of 80%, and a significance
level of 0.05 (with a two-sided paired t-test). A target
number of 100 registered patients was thus set to ac-
count for patients who may not complete the study.
Procedure
Data were collected through self-administered question-
naires before and after pharmacists’ provision of informa-
tion. At Tokyo Medical University hospital, the therapeutic
strategy was determined by physicians or a team confer-
ence that includes pharmacists. First, treating physicians
met with patients and recommended the therapeutic strat-
egy. Next, pharmacists met with patients and asked to
complete the DCS and then left patients. At least one hour
later, pharmacists returned and asked patients to complete
the DCS a second time to address the RTM. After patients
completed the survey for a second time, pharmacists pro-
vided information to patients for all treatment options.
This information mainly consisted of the aim of treatment,
side effects, and supportive care for the most highly
recommended treatment option, and was relayed without
a specific protocol. After the pharmacist has provided the
necessary information, patients then completed the DCS a
third time, the EORTC QLQ-C30, and the questionnaire
regarding socio-demographics. Nine pharmacists (3 men
and 6 women) were involved in this study. The mean
(S.D.) age and work experience of these pharmacists were
30.8 (2.4) years and 7.6 (2.1) years, respectively. The mean
length of discussion was 30 ± 11.8 min. After receiving in-
formation from the pharmacists’, the patients then decided
about treatment with their physicians.
Analysis
Reliability and validity were investigated by using the aver-
age score on the first two DCSs to address RTM. The reli-
ability of the five subscales was estimated by calculating
Cronbach’s alpha. A Cronbach’s alpha value of >0.7 was
considered acceptable. Construct validity, which refers to
the ability of a measurement tool to actually measure the
psychological concept being studied, was assessed through
item-domain correlation and multi-trait scaling analysis
for convergent validity and discriminant validity. Conver-
gent validity tests whether constructs that should be re-
lated are related and discriminant validity tests whether
believed unrelated constructs are, in fact, unrelated. Both
are considered subcategories or subtypes of construct val-
idity. A correlation of 0.4 or greater between an item and
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the correlation of the same item with a different domain,
is required for convergent validity. Pearson correlation co-
efficient was calculated for the item-domain correlation to
check the correlation of each item in a given scale for con-
vergent validity and discriminant validity and for correl-
ation between the score on each scale of the DCS and the
scores on the EORTC QLQ-C30. Cluster analysis was
conducted to examine the factorial structure of the DCS.
We hypothesized that the optimal number of clusters was
five, based on the DCS subscale number, and used SAS
(version 9.1.3, SAS Institute Inc. Cary, North Carolina)
VARCLUS procedure, which is a method for clustering
variables. While the conventional clustering method di-
vides observation into clusters, the VARCLUS produces
readily interpretable disjoint clusters [27]. A paired t-test
was used to analyze the change in DCS score before and
after pharmacists’ provision of information. Descriptive
statistics, including mean and standard deviation, were
used to summarize patient demographics. Reliability and
validity were analyzed using SAS, with the other statistics
analyzed through JMP (version 9.02, SAS Institute Inc.
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patients gave written informed consent. The protocol was
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One hundred inpatients participated between June 2011
and April 2012. We excluded the data of six patients
from analysis due to deviation from protocol; two were
not administered the second DCS and four completed
only one side of a double-sided questionnaire. Thus, 94
patients (94%) were ultimately included in the analysis.
Participants’ basic characteristics are shown in Table 1.
The average age of a patient was 58.1 ± 11.0 years with a
range of 32–74 years. Female patients dominated the
sample. Half of the patients were recommended for ad-
juvant chemotherapy and 27% of the patients had previ-
ously received chemotherapy treatment.Reliability
To assess internal consistency, Cronbach’s alpha coeffi-
cient was calculated. Internal consistency was high for
all domains of the DCS (Cronbach’s alpha of 0.84–0.96)
and satisfactory for all evaluated items (Table 2).Validity
Item-domain correlation was nearly equal for each item
in the four subscales of uncertainty, informed, values
clarity, and effective decision. The coefficient of item-
domain correlation for item 8 and the support subscale
(0.63) was relatively lower than that for items 7 (0.70)
and 9 (0.80). The criterion of convergent validity and
discriminant validity were met in all domains. The re-
sults of the cluster analysis are presented in Table 3. All
items on the values clarity subscale were contained in
Cluster 1 while Cluster 2 consisted of items on the un-
certainty and effective decision subscales. Cluster 3
consisted of items 7, 9, and 13. Cluster 4 consisted of
only item 8. Of items belonging to the informed domain,
Table 2 Internal consistency of Decisional Conflict Scale domains
Domain* (%) Item no. Cronbach’s alpha Item-domain correlation Convergent validity** (%) Discriminant validity***
Uncertainty 10 0.91 0.83 100 100
11 0.85
12 0.80
Informed 1 0.90 0.82 100 100
2 0.86
3 0.74
Values clarity 4 0.96 0.90 100 100
5 0.93
6 0.90
Support 7 0.84 0.70 100 100
8 0.63
9 0.80




*Average score of the DCS before pharmacists’ provision of information.
**The percentage of items that passed the test of convergent validity.
***The percentage of items that passed the test of discriminant validity.
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(“I know the risk and side effects of each option”) was
grouped in Cluster 1. The inter-cluster correlations of
Clusters 1–2, 1–3, 1–5, 2–3, 2–5, and 3–5 were above
0.7. In contrast, the inter-cluster correlations that in-
cluded Cluster 4 were relatively low (Cluster 1–4 [0.62],
Cluster 2–4 [0.66], and Cluster 3–4 and 4–5 [0.64]).Correlation between DCS and QOL
With respect to baseline QOL, the mean (SD) of global
health status (GHS)/QOL was 55.1 (23.2). All Spearman
correlation coefficients between each DCS score and the
EORTC QLQ-C30, including GHS/QOL, function
scores, and symptom scores, were not above 0.4; there-
fore, no correlations were observed between decisional
conflict and QOL.Influence of pharmacists’ provision of information
The mean (SD) of the total score at baseline, 40.2 (21.1),
was significantly reduced to 31.7 (20.5) after factoring in
pharmacists’ provision of information (p < 0.001, paired
t-test) (Table 4). Similarly, the scores on the subscales of
uncertainty (45.0 vs. 37.2; difference: -8.5, p < 0.0001), in-
formed (40.3 vs. 31.9; difference: -7.8, p < 0.0001), values
clarity (44.2 vs. 32.1; difference: -12.1, p < 0.0001), sup-
port (37.2 vs. 29.4; difference: -7.8, p < 0.0001), and ef-
fective decision (35.7 vs. 28.7; difference: -7.0, p <
0.0001) decreased significantly. A similar trend was ob-
served across pharmacists. The standardized responsemean and effect size of the total score were 0.6 and 0.4,
respectively.
Discussion
In this study, we evaluated the psychometric properties
of the Japanese version of the DCS and the influence of
pharmacists’ information on decisional conflict among
patients with cancer who were recommended to initiate
a new chemotherapy regimen. The Japanese version of
the DCS showed high reliability and validity and was
influenced by pharmacists’ provision of information.
The Japanese version of the DCS has acceptable con-
vergent and discriminant validity and acceptable internal
consistency. However, regarding construct validity, items
of the Japanese version of the DCS were not clustered
similar to the original version of the DCS. In particular,
items of uncertainty and effective decision were in the
same cluster. There are several potential causes for this
dissimilarity. Firstly, half of the participants were
recommended to receive adjuvant chemotherapy. Gener-
ally, physicians strongly recommend patients receive ad-
juvant chemotherapy; however, patients in palliative
settings have the added option of watchful waiting [28].
Hence, almost all inpatients recommended to receive ad-
juvant chemotherapy in this study may have been close
to not having a choice of no treatment. Koedoot et al.
have described the problem with using the effective deci-
sion subscale in the decision-making process with these
cases [29]. Because we aimed to evaluate the effect of
the pharmacists’ provision of information on decision-
Table 3 Cluster structure of Decisional Conflict Scale items
Domain Item no. Cluster structure
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
Uncertainty 10 0.79 0.89 0.79 0.68 0.77
11 0.66 0.90 0.72 0.60 0.63
12 0.61 0.89 0.61 0.46 0.57
Informed 1 0.78 0.65 0.72 0.63 0.96
2 0.83 0.70 0.75 0.60 0.96
3 0.87 0.54 0.63 0.50 0.74
Values clarity 4 0.94 0.76 0.80 0.60 0.83
5 0.96 0.73 0.76 0.60 0.79
6 0.94 0.69 0.78 0.60 0.75
Support 7 0.69 0.60 0.88 0.53 0.65
8 0.62 0.66 0.64 1.00 0.64
9 0.71 0.71 0.93 0.66 0.73
Effective decision 13 0.76 0.79 0.89 0.54 0.69
14 0.56 0.79 0.54 0.57 0.51
15 0.65 0.89 0.75 0.65 0.59
16 0.60 0.90 0.67 0.55 0.63
Variation explained* (%) 86.3 77.3 81.3 100.0 91.9
Inter-Cluster Cluster 1-2 Cluster 1-3 Cluster 1-4 Cluster 1-5
Correlation 0.73 0.80 0.62 0.84
Cluster 2-3 Cluster 2-4 Cluster 2-5
0.78 0.66 0.70




Correlation coefficients between each item and each cluster component.
Bold characters indicate the highest correlation coefficients.
*Total variation explained = 83.5%.
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ician counseling. Thus, the results of the cluster analysis
may be affected by the timing of the administration of
the DCS. Secondly, our study included patients with dif-
ferent types of cancer (i.e., breast, lung, or gynecological)Table 4 Differences in Decisional Conflict Scale domain score
information
Mean (SD) score Difference
Pre Post Mean SE
Total score 40.2 (21.1) 31.7 (20.5) −8.5 1.3
Uncertainty 45.0 (23.6) 37.2 (24.5) −7.8 1.6
Informed 40.3 (23.8) 31.9 (24.0) −8.4 1.7
Values clarity 44.2 (25.2) 32.1 (24.2) −12.1 1.8
Support 37.2 (22.2) 29.4 (21.0) −7.8 1.6
Effective decision 35.7 (22.1) 28.7 (20.8) −7.0 1.4
*(pre-post)/SD (pre-post), **(pre-post)/SD (pre), ***Paired t-test.
SD; Standard deviation, SE; Standard error.and settings (i.e., adjuvant or palliative). The number of
treatment options and need for chemotherapy usually
depend on the type of cancer and settings, which would
affect decisional conflict. Thus, the results of cluster








5 0.6 0.4 −6.3 <.0001
2 0.5 0.3 −4.8 <.0001
4 0.5 0.4 −4.8 <.0001
8 0.7 0.5 −6.4 <.0001
0 0.5 0.3 −4.9 <.0001
6 0.5 0.3 −4.8 <.0001
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decision control. The patients’ role in a decision is asso-
ciated with their decision characteristics and differs
according to evidence of treatment, treatment modality,
and palliative settings [30]. Indeed, Watanabe and col-
leagues found that the preferences of Japanese patients
with cancer varied with their role in decision making,
similar to patients in Western countries [19]. Therefore,
future studies could consider the relationship between
preferred role and effective decision through the Control
Preference Scale developed by Degner et al [31].
Pharmacists’ provision of information in this study,
which is not a special intervention but a daily practice,
had a much greater impact on the values clarity and in-
formed subscales. On the other hand, the differences in
the uncertainty, support, and effective decision subscales
before and after pharmacists’ provision of information
were not as large. A factor affecting the difference of im-
provement between these subscales is the content of the
information provided by the pharmacists. Pharmacists
generally provide treatment information with a focus on
treatment efficacy and side effects [32]. However, pa-
tients would usually consider the influence of treatment
on social aspects (e.g., family, partner, work, home du-
ties, and social activity) as side effects as well [33]. Phar-
macists may be better able to provide this information
along with the medical aspects. The lack of a correlation
between QOL and decisional conflict also indicated that
patients recommended for a new chemotherapy regimen
are facing problems that are not measured by QOL
instruments.
Taken together, our results indicate that pharmacists’
provision of information can contribute to shared deci-
sion making. Although the pharmacist’s role and respon-
sibility as part of the cancer care team is developing and
differs slightly for each country, decisional conflict has
the potential to become a new aspect of pharmacist
intervention. Unfortunately, the concept of shared deci-
sion making is not widely recognized in Japan. In order
to improve decisional conflict and facilitate shared deci-
sion making, further studies are needed to determine the
information that patients require in order to improve
the quality of the information provided by pharmacists.
Limitations
We acknowledge several limitations in our study. First, we
were unable to examine criterion-related validity because
there is no alternative scale to measure decisional conflict
in Japanese. Second, our study included patients in differ-
ent chemotherapy settings as well as patients with various
types of cancer. Different treatment regimens and cancer
types may influence the extent or the change of decisional
conflict. Third, we assessed decisional conflict immediately
before and after the pharmacists’ provision of informationto exclude other factors affecting patients’ decisional con-
flict without investigating the appropriateness of assessing
the influence of pharmacists’ provision of information im-
mediately following the pharmacist-patient interaction.
Conclusions
The Japanese version of the DCS appears to be valid and
reliable as a measure for Japanese patients with cancer.
We found that the information provided by pharmacists’
may decrease decisional conflict among patients with
cancer who were recommended a new chemotherapy
regimen. Further parallel group comparison studies are
needed to confirm the influence of the information pro-
vided by pharmacists.
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